Cargando…
Country of birth and non-small cell lung cancer incidence, treatment, and outcomes in New South Wales, Australia: a population-based linkage study
OBJECTIVE: To compare treatment within 12 months of diagnosis, and survival by country of birth for people diagnosed with invasive non-small cell lung cancer (NSCLC) in New South Wales (NSW), Australia. DESIGN, PATIENTS, AND SETTING: A population-based cohort study of NSW residents diagnosed with NS...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9513895/ https://www.ncbi.nlm.nih.gov/pubmed/36163039 http://dx.doi.org/10.1186/s12890-022-02163-z |
_version_ | 1784798165392687104 |
---|---|
author | Little, Alana Roder, David Zhao, George W. Challam, Sheetal Malalasekera, Ashanya Currow, David |
author_facet | Little, Alana Roder, David Zhao, George W. Challam, Sheetal Malalasekera, Ashanya Currow, David |
author_sort | Little, Alana |
collection | PubMed |
description | OBJECTIVE: To compare treatment within 12 months of diagnosis, and survival by country of birth for people diagnosed with invasive non-small cell lung cancer (NSCLC) in New South Wales (NSW), Australia. DESIGN, PATIENTS, AND SETTING: A population-based cohort study of NSW residents diagnosed with NSCLC in 2003–2016 using de-identified linked data from the NSW Cancer Registry, NSW Admitted Patient Data collection, Emergency Departments, Medicare Benefits and Pharmaceutical Benefits Scheme, and National Death Index. MAIN OUTCOME MEASURES: Odds of receiving any treatment, surgery, systemic therapy, or radiotherapy respectively, in the 12 months following diagnosis were calculated using multivariable logistic regression. The hazard of death (all-cause) at one- and five-years following diagnosis was calculated using multivariable proportional hazards regression. RESULTS: 27,114 People were recorded with NSCLC in the 14-year study period. Higher percentages of older males from European countries applied in the earlier years, with a shift to younger people from South East Asia, New Zealand, and the Middle East. Adjusted analyses indicated that, compared with the Australian born, people from European countries were more likely to receive treatment, and, specifically surgery. Also, people from Asian countries were more likely to receive systemic therapy but less likely to receive radiotherapy. Survival at one- and five-years following diagnosis was higher for people born in countries other than Australia, New Zealand the United Kingdom and Germany. CONCLUSIONS: Variations exist in treatment and survival by country of birth in NSW. This may be affected by differences in factors not recorded in the NSW Registry, including use of general health services, family histories, underlying health conditions, other intrinsic factors, and cultural, social, and behavioural influences. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12890-022-02163-z. |
format | Online Article Text |
id | pubmed-9513895 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-95138952022-09-28 Country of birth and non-small cell lung cancer incidence, treatment, and outcomes in New South Wales, Australia: a population-based linkage study Little, Alana Roder, David Zhao, George W. Challam, Sheetal Malalasekera, Ashanya Currow, David BMC Pulm Med Research OBJECTIVE: To compare treatment within 12 months of diagnosis, and survival by country of birth for people diagnosed with invasive non-small cell lung cancer (NSCLC) in New South Wales (NSW), Australia. DESIGN, PATIENTS, AND SETTING: A population-based cohort study of NSW residents diagnosed with NSCLC in 2003–2016 using de-identified linked data from the NSW Cancer Registry, NSW Admitted Patient Data collection, Emergency Departments, Medicare Benefits and Pharmaceutical Benefits Scheme, and National Death Index. MAIN OUTCOME MEASURES: Odds of receiving any treatment, surgery, systemic therapy, or radiotherapy respectively, in the 12 months following diagnosis were calculated using multivariable logistic regression. The hazard of death (all-cause) at one- and five-years following diagnosis was calculated using multivariable proportional hazards regression. RESULTS: 27,114 People were recorded with NSCLC in the 14-year study period. Higher percentages of older males from European countries applied in the earlier years, with a shift to younger people from South East Asia, New Zealand, and the Middle East. Adjusted analyses indicated that, compared with the Australian born, people from European countries were more likely to receive treatment, and, specifically surgery. Also, people from Asian countries were more likely to receive systemic therapy but less likely to receive radiotherapy. Survival at one- and five-years following diagnosis was higher for people born in countries other than Australia, New Zealand the United Kingdom and Germany. CONCLUSIONS: Variations exist in treatment and survival by country of birth in NSW. This may be affected by differences in factors not recorded in the NSW Registry, including use of general health services, family histories, underlying health conditions, other intrinsic factors, and cultural, social, and behavioural influences. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12890-022-02163-z. BioMed Central 2022-09-27 /pmc/articles/PMC9513895/ /pubmed/36163039 http://dx.doi.org/10.1186/s12890-022-02163-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Little, Alana Roder, David Zhao, George W. Challam, Sheetal Malalasekera, Ashanya Currow, David Country of birth and non-small cell lung cancer incidence, treatment, and outcomes in New South Wales, Australia: a population-based linkage study |
title | Country of birth and non-small cell lung cancer incidence, treatment, and outcomes in New South Wales, Australia: a population-based linkage study |
title_full | Country of birth and non-small cell lung cancer incidence, treatment, and outcomes in New South Wales, Australia: a population-based linkage study |
title_fullStr | Country of birth and non-small cell lung cancer incidence, treatment, and outcomes in New South Wales, Australia: a population-based linkage study |
title_full_unstemmed | Country of birth and non-small cell lung cancer incidence, treatment, and outcomes in New South Wales, Australia: a population-based linkage study |
title_short | Country of birth and non-small cell lung cancer incidence, treatment, and outcomes in New South Wales, Australia: a population-based linkage study |
title_sort | country of birth and non-small cell lung cancer incidence, treatment, and outcomes in new south wales, australia: a population-based linkage study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9513895/ https://www.ncbi.nlm.nih.gov/pubmed/36163039 http://dx.doi.org/10.1186/s12890-022-02163-z |
work_keys_str_mv | AT littlealana countryofbirthandnonsmallcelllungcancerincidencetreatmentandoutcomesinnewsouthwalesaustraliaapopulationbasedlinkagestudy AT roderdavid countryofbirthandnonsmallcelllungcancerincidencetreatmentandoutcomesinnewsouthwalesaustraliaapopulationbasedlinkagestudy AT zhaogeorgew countryofbirthandnonsmallcelllungcancerincidencetreatmentandoutcomesinnewsouthwalesaustraliaapopulationbasedlinkagestudy AT challamsheetal countryofbirthandnonsmallcelllungcancerincidencetreatmentandoutcomesinnewsouthwalesaustraliaapopulationbasedlinkagestudy AT malalasekeraashanya countryofbirthandnonsmallcelllungcancerincidencetreatmentandoutcomesinnewsouthwalesaustraliaapopulationbasedlinkagestudy AT currowdavid countryofbirthandnonsmallcelllungcancerincidencetreatmentandoutcomesinnewsouthwalesaustraliaapopulationbasedlinkagestudy |